Published in Cancers (Basel) on February 25, 2010
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell (2009) 13.09
Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev (2004) 11.69
Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science (1997) 10.54
Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature (1990) 7.15
The interleukin-8 pathway in cancer. Clin Cancer Res (2008) 7.12
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res (2002) 4.16
Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development (1995) 4.05
VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med (2005) 3.98
Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol (2009) 3.02
Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol (2001) 2.89
Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol (2003) 2.81
VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood (2006) 2.66
Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. Int J Cancer (2000) 2.64
Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol (2001) 2.58
A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med (2002) 2.55
The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study. Am J Pathol (1988) 2.53
Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res (1996) 2.36
The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest (1995) 2.35
Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res (2007) 2.15
Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol (2004) 2.13
Transforming growth factor-beta in cutaneous melanoma. Pigment Cell Melanoma Res (2008) 2.03
Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol (2002) 1.96
Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci U S A (1998) 1.93
Neovascularization produced by angiotensin II. J Lab Clin Med (1985) 1.93
Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res (2009) 1.93
Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest (2003) 1.79
Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med (1997) 1.72
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res (2008) 1.65
Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol (1998) 1.61
Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest (2003) 1.60
Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res (2009) 1.58
Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res (2000) 1.55
Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res (2009) 1.52
Antiangiogenic and antitumor activities of IL-27. J Immunol (2006) 1.50
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol (2007) 1.49
Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res (2002) 1.47
Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res (2003) 1.46
The history of the angiogenic switch concept. Leukemia (2006) 1.40
Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am J Clin Pathol (2006) 1.39
Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. Eur J Pharmacol (1991) 1.35
Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab Invest (1992) 1.34
Endogenous inhibitors of angiogenesis: a historical review. Leuk Res (2008) 1.34
Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am J Pathol (1995) 1.33
Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis. J Biol Chem (2009) 1.32
Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Res (1995) 1.28
CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br J Cancer (2009) 1.27
The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review. Br J Haematol (2005) 1.25
Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase. J Cutan Pathol (1997) 1.23
Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res (2004) 1.22
The role of the vascular phase in solid tumor growth: a historical review. Neoplasia (1999) 1.20
Loss of activator protein-2alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J Biol Chem (2003) 1.19
Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. Eur J Cancer (2009) 1.19
Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res (1997) 1.17
Lymphatic vessels as targets of tumor therapy? J Exp Med (2001) 1.17
Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med (2002) 1.16
FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer (2006) 1.16
Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression. J Am Coll Surg (2003) 1.15
Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab (2003) 1.15
Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation. FASEB J (2003) 1.14
The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis (2008) 1.13
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer (2005) 1.13
Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol (2002) 1.12
Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther (2005) 1.12
Tumour-associated macrophage infiltration, neovascularization and aggressiveness in malignant melanoma: role of monocyte chemotactic protein-1 and vascular endothelial growth factor-A. Melanoma Res (2005) 1.12
Inflammation and melanoma metastasis. Pigment Cell Melanoma Res (2009) 1.11
Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Hum Pathol (2005) 1.10
Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo. Int J Cancer (2000) 1.09
Melanocyte tumor progression is associated with changes in angiogenesis and expression of the 67-kilodalton laminin receptor. Cancer (1993) 1.09
Analysis of the tumor vasculature and metastatic behavior of xenografts of human melanoma cell lines transfected with vascular permeability factor. Am J Pathol (1996) 1.09
Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor. Am J Pathol (2006) 1.07
Expression of interleukin-8 in primary and metastatic malignant melanoma of the skin. Melanoma Res (1999) 1.06
Angiogenesis is prognostically important in vertical growth phase melanomas. Int J Oncol (1999) 1.05
Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts. Cancer Res (2002) 1.05
Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma. J Exp Clin Cancer Res (2008) 1.04
Vascularity in cutaneous melanoma detected by Doppler sonography and histology: correlation with tumour behaviour. Br J Cancer (1989) 1.04
Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. Proc Natl Acad Sci U S A (2005) 1.04
Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci U S A (2007) 1.03
Paracrine regulation of vascular endothelial growth factor--a expression during macrophage-melanoma cell interaction: role of monocyte chemotactic protein-1 and macrophage colony-stimulating factor. J Interferon Cytokine Res (2005) 1.03
Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells. Cancer Res (2007) 1.03
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol (2003) 1.03
Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Res (2005) 1.03
Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Eur J Cancer (2009) 1.02
Thrombospondin-1-mediated metastasis suppression by the primary tumor in human melanoma xenografts. J Invest Dermatol (2001) 1.00
The implication of platelet activating factor in cancer growth and metastasis: potent beneficial role of PAF-inhibitors and antioxidants. Infect Disord Drug Targets (2009) 1.00
Cutaneous malignant melanoma: correlation between neovascularization and peritumor accumulation of mast cells overexpressing vascular endothelial growth factor. Hum Pathol (2000) 0.99
Hypoxia-associated spontaneous pulmonary metastasis in human melanoma xenografts: involvement of microvascular hot spots induced in hypoxic foci by interleukin 8. Br J Cancer (2002) 0.99
Platelet-derived growth factor-receptor alpha strongly inhibits melanoma growth in vitro and in vivo. Neoplasia (2009) 0.98
Monocyte/macrophage recruitment, activation and differentiation modulate interleukin-8 production: a paracrine role of tumor-associated macrophages in tumor angiogenesis. In Vivo (2002) 0.98
Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization. Cancer Sci (2007) 0.96
Immune cells and angiogenesis. J Cell Mol Med (2009) 0.96
VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course. Melanoma Res (2002) 0.95
The vascularity of primary cutaneous melanoma. J Pathol (1991) 0.93
Platelet-activating factor inactivation by local expression of platelet-activating factor acetyl-hydrolase modifies tumor vascularization and growth. Clin Cancer Res (2003) 0.92
Mast cells and angiogenesis in gastric carcinoma. Int J Exp Pathol (2010) 1.09
Neovascularization and mast cells with tryptase activity increase simultaneously in human pterygium. J Cell Mol Med (2007) 0.99
Enalapril treatment discloses an early role of angiotensin II in inflammation- and oxidative stress-related muscle damage in dystrophic mdx mice. Pharmacol Res (2011) 0.96
Cancer survivorship: long-term side-effects of anticancer treatments of gastrointestinal cancer. Curr Opin Oncol (2015) 0.94
HIF activation and VEGF overexpression are coupled with ZO-1 up-phosphorylation in the brain of dystrophic mdx mouse. Brain Pathol (2007) 0.92
Beta amyloid angiogenic activity in vitro and in vivo. Int J Mol Med (2007) 0.91
HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target. Clin Cancer Res (2013) 0.87
Epo is involved in angiogenesis in human glioma. J Neurooncol (2010) 0.84
Macrophages and angiogenesis in rheumatic diseases. Vasc Cell (2013) 0.84
Aquaporin-4 contributes to the resolution of peritumoural brain oedema in human glioblastoma multiforme after combined chemotherapy and radiotherapy. Eur J Cancer (2009) 0.83
Intussusceptive microvascular growth in human glioma. Clin Exp Med (2009) 0.81
The Chick Embryo Chorioallantoic Membrane as an In Vivo Assay to Study Antiangiogenesis. Pharmaceuticals (Basel) (2010) 0.80
Erythropoietin is involved in angiogenesis in human primary melanoma. Int J Exp Pathol (2010) 0.79
Glial dystrophin-associated proteins, laminin and agrin, are downregulated in the brain of mdx mouse. Lab Invest (2010) 0.78
Schwann cells in neuroblastoma express erythropoietin. J Neurooncol (2006) 0.78
Effects of prednisolone on the dystrophin-associated proteins in the blood-brain barrier and skeletal muscle of dystrophic mdx mice. Lab Invest (2013) 0.77
Tryptase- and leptin-positive mast cells correlate with vascular density in uterine leiomyomas. Am J Obstet Gynecol (2007) 0.76
Angiogenesis and hyperbaric oxygen in the chick embryo chorioallantoic membrane. Int J Dev Biol (2015) 0.76
Aquaporin-4 expression in primary human central nervous system lymphomas correlates with tumour cell proliferation and phenotypic heterogeneity of the vessel wall. Eur J Cancer (2011) 0.76
Novel lenalidomide-based combinations for treatment of multiple myeloma. Crit Rev Oncol Hematol (2012) 0.75
Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma. Pharmaceuticals (Basel) (2010) 0.75
Angiogenesis in unknown primary tumors. Clin Exp Med (2011) 0.75
[Bone health in the oncologic patient]. Recenti Prog Med (2012) 0.75